Phenytoin age-dose-concentration relationship in children

Area of Science:

• Pharmacology
• Pediatric Medicine
• Clinical Pharmacy

Background:

• Phenytoin is a widely used antiepileptic drug in pediatric populations.
• Achieving and maintaining therapeutic phenytoin concentrations is crucial for efficacy and safety.
• Pediatric dosing of phenytoin can be challenging due to pharmacokinetic variability.

Purpose of the Study:

• To analyze phenytoin steady-state concentrations in children.
• To investigate age-related pharmacokinetic differences in phenytoin elimination.
• To assess the impact of comedications on phenytoin pharmacokinetics.

Main Methods:

• Retrospective analysis of 423 phenytoin steady-state concentrations from a therapeutic drug monitoring database (1984-1990).
• Evaluation of Michaelis-Menten pharmacokinetic parameters (Vmax, Km) in patients with multiple dose-concentration measurements.
• Analysis of age-dose-concentration relationships and influence of comedications.

Main Results:

• Only 43% of pediatric patients achieved therapeutic phenytoin concentrations (10-20 mg/L).
• Many children, especially those under 3 years, had sub-therapeutic concentrations despite standard doses (4-8 mg/kg/day).
• Phenytoin maximal elimination rate (Vmax) significantly decreased with age, while the Michaelis constant (Km) showed no age dependency. Comedications did not affect Vmax or Km.

Conclusions:

• Standard pediatric phenytoin dosing regimens may not ensure therapeutic concentrations in all children.
• Age is a significant factor influencing phenytoin elimination, with reduced Vmax in older children.
• Individualized phenytoin dosing, considering age, is recommended for optimal therapeutic outcomes in pediatric patients.